AGMB Aligns With FDA
Agomab Therapeutics aligns with FDA on design of Phase 2b NOV-ERA study with Ontunisertib
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Agomab Therapeutics aligns with FDA on design of Phase 2b NOV-ERA study with Ontunisertib
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.